VIVANZAPharmaceuticals
Vivanza Biosciences Ltd — Profit & Loss Statement
₹1.76
+0.00%
Vivanza Biosciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -60657.08 | -441.51 | — |
| Tax Rate For Calcs | 0.30 | 0.21 | 0.16 | 0.00 | — |
| Normalized EBITDA | -0.30 Cr | 1.12 Cr | 1.17 Cr | 0.78 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -0.04 Cr | -0.04 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -0.04 Cr | -0.04 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | -0.67 Cr | 0.55 Cr | 0.60 Cr | 0.33 Cr | — |
| Reconciled Depreciation | 0.01 Cr | 0.01 Cr | 26000.00 | 74000.00 | — |
| Reconciled Cost Of Revenue | 6.82 Cr | 25.95 Cr | 16.51 Cr | 9.65 Cr | — |
| EBITDA | -0.30 Cr | 1.12 Cr | 1.14 Cr | 0.75 Cr | — |
| EBIT | -0.31 Cr | 1.11 Cr | 1.14 Cr | 0.74 Cr | — |
| Net Interest Income | -0.35 Cr | -0.41 Cr | -0.43 Cr | -0.43 Cr | — |
| Interest Expense | 0.35 Cr | 0.41 Cr | 0.42 Cr | 0.41 Cr | — |
| Normalized Income | -0.67 Cr | 0.55 Cr | 0.63 Cr | 0.37 Cr | — |
| Net Income From Continuing And Discontinued Operation | -0.67 Cr | 0.55 Cr | 0.60 Cr | 0.33 Cr | — |
| Total Expenses | 7.80 Cr | 26.78 Cr | 17.08 Cr | 10.32 Cr | — |
| Diluted NI Availto Com Stockholders | -0.67 Cr | 0.55 Cr | 0.60 Cr | 0.33 Cr | — |
| Net Income Common Stockholders | -0.67 Cr | 0.55 Cr | 0.60 Cr | 0.33 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -0.67 Cr | 0.55 Cr | 0.60 Cr | 0.33 Cr | — |
| Net Income Including Noncontrolling Interests | -0.67 Cr | 0.55 Cr | 0.60 Cr | 0.33 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | -0.67 Cr | 0.55 Cr | 0.60 Cr | 0.33 Cr | — |
| Tax Provision | 84000.00 | 0.15 Cr | 0.12 Cr | 4000.00 | — |
| Pretax Income | -0.67 Cr | 0.70 Cr | 0.72 Cr | 0.33 Cr | — |
| Other Non Operating Income Expenses | 0.06 Cr | 0.05 Cr | 0.48 Cr | 0.83 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -0.04 Cr | -0.04 Cr | — |
| Net Non Operating Interest Income Expense | -0.35 Cr | -0.41 Cr | -0.43 Cr | -0.43 Cr | — |
| Interest Expense Non Operating | 0.35 Cr | 0.41 Cr | 0.42 Cr | 0.41 Cr | — |
| Operating Income | -0.38 Cr | 1.05 Cr | 0.73 Cr | 0.08 Cr | — |
| Operating Expense | 0.98 Cr | 0.83 Cr | 0.57 Cr | 0.66 Cr | — |
| Other Operating Expenses | 0.39 Cr | 0.37 Cr | 0.11 Cr | 0.18 Cr | — |
| Depreciation And Amortization In Income Statement | 0.01 Cr | 0.01 Cr | 26000.00 | 74000.00 | — |
| Depreciation Income Statement | 0.01 Cr | 0.01 Cr | 26000.00 | 74000.00 | — |
| Gross Profit | 0.60 Cr | 1.89 Cr | 1.30 Cr | 0.75 Cr | — |
| Cost Of Revenue | 6.82 Cr | 25.95 Cr | 16.51 Cr | 9.65 Cr | — |
| Total Revenue | 7.42 Cr | 27.84 Cr | 17.81 Cr | 10.40 Cr | — |
| Operating Revenue | 7.42 Cr | 27.84 Cr | 17.81 Cr | 10.40 Cr | — |
| Interest Income | — | 0.00 | 0.00 | 0.00 | 0.42 Cr |
| Rent Expense Supplemental | — | 0.00 | 0.01 Cr | 0.02 Cr | 50000.00 |
| Diluted Average Shares | — | 3.91 Cr | 4.00 Cr | 4.00 Cr | 4.00 Cr |
| Basic Average Shares | — | 3.91 Cr | 4.00 Cr | 4.00 Cr | 4.00 Cr |
| Diluted EPS | — | 0.14 | 0.15 | 0.08 | 0.02 |
| Basic EPS | — | 0.14 | 0.15 | 0.08 | 0.02 |
| Write Off | — | 0.04 Cr | 0.04 Cr | 0.04 Cr | 0.04 Cr |
| Total Other Finance Cost | — | 59000.00 | 68000.00 | 0.03 Cr | 67828.00 |
| Interest Income Non Operating | — | 0.00 | 0.00 | 0.00 | 0.42 Cr |
| Selling General And Administration | — | 0.19 Cr | 0.09 Cr | 0.15 Cr | 0.13 Cr |
| Selling And Marketing Expense | — | 0.15 Cr | 0.06 Cr | 0.10 Cr | 50087.00 |
| General And Administrative Expense | — | 0.03 Cr | 0.03 Cr | 0.06 Cr | 0.12 Cr |
| Rent And Landing Fees | — | 0.00 | 0.01 Cr | 0.02 Cr | 50000.00 |
| Minority Interests | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Vivanza Biosciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.